EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication

Ing S Tiong iD, Sun Loo

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24054790 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Ing S Tiong und 1 weiteren Autor:innen. Beteiligte Einrichtung: Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Measurable residual disease (MRD) assessment in acute myeloid leukemia (AML) has an established role in disease prognostication, particularly in guiding decisions for hematopoietic cell transplantation in first remission. Serial MRD assessment is now routinely recommended in the evaluation of treatment response and monitoring in AML by the European LeukemiaNet. The key question remains, however, if MRD in AML is clinically actionable or “does MRD merely portend fate”? With a series of new drug approvals since 2017, we now have more targeted and less toxic therapeutic options for the potential application of MRD-directed therapy. Recent approval of NPM1 MRD as a regulatory endpoint is also foreseen to drastically transform the clinical trial landscape such as biomarker-driven adaptive design. In this article, we will review (1) the emerging molecular MRD markers (such as non-DTA mutations, IDH1/2, and FLT3-ITD); (2) the impact of novel therapeutics on MRD endpoints; and (3) how MRD might be used as a predictive biomarker to guide therapy in AML beyond its prognostic role, which is the focus of two large collaborative trials: AMLM26 INTERCEPT (ACTRN12621000439842) and MyeloMATCH (NCT05564390).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHumansHematopoietic Stem Cell TransplantationNeoplasm, ResidualNuclear ProteinsNucleophosminRemission InductionPrognosisBiomarkers, Tumor

Stichwörter der Autor:innen

AMLMRDNPM1novel therapyrelapse

Substanzen

Nuclear ProteinsNucleophosminNPM1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
  • The Alfred Hospital, Melbourne, VIC 3004, Australia.
  • Australian Centre for Blood Diseases, Monash University, Melbourne, VIC 3004, Australia.
  • Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
  • The Northern Hospital, Epping, VIC 3076, Australia.

ORCID-Profile: Ing S Tiong

Zitieren

APA

Tiong, I. S., & Loo, S. (2023). Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24054790

Vancouver

Tiong IS, Loo S. Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24054790

BibTeX
@article{Tiong2023,
  author = {Tiong, Ing S and Loo, Sun},
  title = {Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24054790}
}
Kostenlos starten →